Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03053999

Enrollment

Registered

2017-02-15

Start date

2012-10-09

Completion date

2023-10-31

Last updated

2019-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Endocrine Neoplasia, Pancreatic Neuroendocrine Tumors, Hyperparathyroidism

Keywords

Multiple Endocrine Neoplasia, Pancreatic Neuroendocrine Tumors, Hyperparathyroidism, HPTH, PNET, Biomarkers, Parathyroidectomy, Genome sequencing, Data review

Brief summary

The study aims to identify predictors of disease in patients with hyperparathyroidism (HPTH) who undergo surgery.

Detailed description

Researchers aim to identify somatic mutations and inherited genetic variants which may help predict the development of PNET in patients with hyperparathyroidism.

Interventions

OTHERGenome Sequencing

Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.

OTHERData Review

Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels).

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. MEN1 patients who have undergone parathyroidectomy and did not develop PNET. 2. MEN1 patients who have undergone parathyroidectomy and had surgical removal of PNET.

Exclusion criteria

N/A

Design outcomes

Primary

Measure	Time frame
Identification of Somatic Mutations and Inherited Genetic Variants to Help Predict the Development of Pancreatic Neuroendocrine Tumors (PNET) in Participants with Hyperparathyroidism by Genome Sequencing	10 years

Secondary

Measure	Time frame
Identification of Somatic Mutations and Inherited Genetic Variants to Help Predict the Development of Pancreatic Neuroendocrine Tumors (PNET) in Participants with Hyperparathyroidism by Data Review	10 years

Countries

United States

Contacts

Primary ContactNancy D. Perrier, MD

NPerrier@mdanderson.org713-792-6940

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026